|
#166
05.04.2006, 21:42
|
|||
|
|||
|
Óâàæàåìûé Àëåêñàíäð, òîãäà íå ïîíÿòíî - ïðè÷åì òóò âîîáùå êðèç? Âàø ïåðâûé ïðèìåð - êòî ñêàçàë, ÷òî ýòî êðèç? À ïîñìîòðèòå, ïîæàëóéñòà, íàçâàíèå èññëåäîâàíèÿ...
Íàâåðíîå, ÿ ÷åãî òî íå ïîíÿë. Ìîæåò, óâàæàåìûé Èãîðü ðàñòîëêóåò. Öèòàòà:
 Õîòÿ â ëþáîì ñëó÷àå, ñïàñèáî Âàì çà êëèíè÷åñêèå ïðèìåðû - èõ âñåãäà î÷åíü èíòåðåñíî è ïîëåçíî ÷èòàòü. Öèòàòà:
P.S. À ïî÷åìó âòîðîìó ïàöèåíòó Áàêòðèì? Ìíå êàê òî êàçàëîñü, ÷òî åìó îñòàëîñü ìåñòî òîëüêî ïðè ïíåâìîöèñòíîé ïíåâìîíèè... 
|
|
#167
05.04.2006, 22:14
|
|||
|
|||
|
Ìåæäó áåññèìïòîìíûì ïîâûøåíèåì ÀÄ áîëåå 180/110 Hg è äèññåêöèåé àîðòû (ÎÍÌÊ, ÈÌ) áîëüøîé âðåìåííîé, êëèíè÷åñêèé è ò.ä. ïðîìåæóòîê.  ýòîé "ñåðîé" çîíå ìíîãî íàøèõ ïàöèåíòîâ, öåëü ðàáîòû - îòâåò íà âîïðîñ "êàê ïðàâèëüíî ñåáÿ âåñòè â ýòîé ñèòóàöèè? êàêîé èç ãèïîòåíçèâíûõ ïðåïàðàòîâ áóäåò íàèáîëååå áåçîïàñåí è ýôôåêòèâåí?".  ïðèíöèïå, ïðàâîìåðåí âîïðîñ "à íóæíî ëè âîîáùå ëå÷èòü òàêèõ ïàöèåíòîâ èëè äîñòàòî÷íî â ïëàíîâîì ïîðÿäêå óñèëèòü ãèïîòåíçèâíóþ òåðàïèþ?", íî ñ ïëàöåáî ðåøèëè ïî ýòè÷åñêèì ñîîáðàæåíèÿì íå ñâÿçûâàòüñÿ, òåì áîëåå, ÷òî ïèëîòíûå èññëåäîâàíèÿ áûëè è ïëàöåáî ïðîèãðàëî â ïëàíå ñíèæåíèÿ ÀÄ.
|
|
#168
06.04.2006, 10:18
|
|||
|
|||
|
Öèòàòà:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Recommendations After reviewing the available clinical data as of 1999 and classifying it by quality of evidence, the IDSA published guidelines for the use of antimicrobial agents to treat women with UTI.24 The American Urological Association and the European Society of Clinical Microbiology and Infectious Diseases have endorsed these guidelines,2,17 which can be summarized into four main recommendations. First, the IDSA recommends a three-day course of double-strength TMP-SMX as empiric therapy in areas where E. coli resistance rates are below 20 percent. Second, although it recognizes that they have efficacy rates similar to TMP-SMX, the IDSA does not recommend fluoroquinolones as universal first-line agents because of resistance concerns. Third, the IDSA recommends a seven-day course of nitrofurantoin or a single dose of fosfomycin as reasonable treatment alternatives. Finally, the IDSA does not recommend the use of beta-lactams because multiple studies have shown them to be inferior when compared with other treatments.
|
|
#169
07.04.2006, 20:05
|
|||
|
|||
|
Óâàæàåìûé Èãîðü, ïðîñòèòå çàíóäñòâî, íî ÿ âñå ðàâíî íå ïîíÿë (à ïîíÿòü õî÷åòñÿ è ïîó÷àñòâîâàòü òîæå, ïðåäâàðèòåëüíûé íåîôèöèàëüíûé ðàçãîâîð ñ ïðîðåêòîðîì óæå ñîñòîÿëñÿ). Òàê âîò.  íàçâàíèè èññëåäîâàíèÿ ñëîâî «êðèç». Íî «áåññèìïòîìíîå ïîâûøåíèå ÀÄ áîëåå 180/110 Hg» - ýòî è áóäåò îïðåäåëåíèåì êðèçà? À åñëè ýòî ïðåñëîâóòîå «ðàáî÷åå äàâëåíèå» íå ëå÷åííîãî ãèïåðòîíèêà? Êàê â ïåðâîì ïðèìåðå óâàæàåìîãî Àëåêñàíäðà. Äëÿ òàêîãî ïàöèåíòà êðèçîì áóäåò óæå íå÷òî èíîå… Òàê ÷òî ïîêà ñ ôîðìóëèðîâêàìè ìíå íå âñå ïîíÿòíî...
|
|
#170
07.04.2006, 20:40
|
|||
|
|||
|
Öèòàòà:
|
|
#171
08.04.2006, 13:26
|
|||
|
|||
|
Óâàæàåìûé Èãîðü, ýòî íè÷åãî íå ìåíÿåò. Áîã ñ íåé, ñ íåêîíòðîëèðóåìîé. Îïèñàíà ñèòóàöèÿ ñ ÍÅ ËÅ×ÅÍÍÛÌ ïàöèåíòîì, ïðèøåäøèì íà ïðèåì è èìåþùèì ÏÎÑÒÎßÍÍÎ ÀÄ 190/110. Îí áóäåò âêëþ÷åí? Åñëè îòâåò "Äà", òî ñëåäóþùèé âîïðîñ - ïðè ÷åì òóò êðèç? Èì è íå ïàõíåò...
|
|
#172
08.04.2006, 19:07
|
|||
|
|||
|
Öèòàòà:
|
|
#173
10.12.2006, 13:49
|
|||
|
|||
|
Ñ íîÿáðÿ-äåêàáðÿ 2006 ñòàðòóåò ÎÑÀÄÀ.
Êîëëåãè, ïðèâåòñâóåòñÿ ó÷àñòèå ËÞÁÎÃÎ çàèíòåðåñîâàííîãî öåíòðà, êëèíèêè è ãîðîäà. Êàðòà ïî ïåðâîé ÷àñòè ðàáîòû î÷åíü ïðîñòàÿ (1 ëèñò!), çàïîëíåíèå å¸ çàíèìàåò 3-4 ìèíóòû. Ïëàíèðóåñÿ ðåãèñòðàöèÿ â êàòàëîãå ÂÍÎÊ [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] è íà ClinicalTrials.gov [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]. Çàÿâêè ìîæíî êèäàòü â ëè÷êó èëè íà [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]. Ñêà÷àòü êàðòó è óçíàòü îá èññëåäîâàíèè ïîäðîáíåå ìîæíî íà [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ].
Ïðèñîåäèíÿéòåñü!
|
Ëèíåéíûé âèä
